Keywords
vitamin d;
antibodies;
plasminogen activator inhibitor 1;
inflammation mediators.
References
Hao JB, Imam S, Dar P, Alfonso-Jaume M, Elnagar N, Jaume JC. Extreme insulin resistance from insulin antibodies (not insulin receptor antibodies) successfully treated with combination immunosuppressive therapy. Diabetes Care 2017; 40(2): e19–e20.
Maiza J, Caron-Debarle M, Vigouroux C, Schneebeli S. Anti-insulin receptor antibodies related to hypoglycemia in a previ-ously diabetic patient. Diabetes Care 2013; 36(6): e77.
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Endocrine Society Evaluation and man-agement of adult hypoglycemic disorders: an Endocrine Socie-ty Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94(3): 709–28.
Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on in-sulin resistance in patients with type 2 diabetes. Diabetol Metab Syndr 2013; 5(1): 8.
Pittas AG, Dawson-Hughes B, Li T, Van DR, Willett WC, Man-son JE, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29(3): 650–6.
Scragg R, Sowers MF, Bell C. Serum 25-hydroxyvitamin D, dia-betes and ethnicity in the third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27(12): 2813–8.
Jennersjö P, Guldbrand H, Björne S, Länne T, Fredrikson M, Lindström T, et al. A prospective observational study of all-cause mortality in relation to serum 25-OH vitamin D3 and parathyroid hormone levels in patients with type 2 diabetes. Diabetol Metab Syndr 2015; 7: 53.
de Boer IH. Vitamin D and glucose metabolism in chronic kid-ney disease. Curr Opin Nephrol Hypertens 2008; 17(6): 566–72.
Shet JJ, Shah A, Sheth FJ, Tivedi S, Lele M, Shah N, et al. Does vitamin D play a siglificant role in type 2 diabetes? BNC En-docr Disord 2015; 15: 5.
Ahmedieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: A relation to disease control and complication. ISRN Endocrinol 2013; 2013: 641098.
Zoppini G, Galletti A, Targher G, Brangani C, Pichiri I, Trombetta M, et al. Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complication in pa-tients with type 2 diabetes. BMJ Op Diab Res Car 2015; 3: 58.
Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mech-anisms for inflammatory damage in chronic disorders. QJM 2002; 95(12): 787–96.
Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302(6): F647–57.
Li YC, Kong J, Wei M, Chen Z, Liu SQ, Cao L. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2): 229–38.
Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li JC. Combina-tion therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105(41): 15886–901.
Suzuki A, Kotake M, Ono Y, Kato T, Oda N, Hayakawa N, et al. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. En-docr J 2006; 53(4): 503–10.
Taverna MJ, Selam J, Slama G. Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes. J Clin Endocrinol Metab 2005; 90(8): 4803–8.
Inuki T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Alterations in serum levels of 1alfa, 25(OH)2D and osteocalcin in pa-tients wwith early diabetic nephropathy. Diab Res Clin Pract 2005; 38(1): 53–9.
Jee D, Han K, Kim EC. Inverse association between high blood 25-hydroxyvitamin D levels and diabetic retinopathy in a rep-resentative Korean population. PLoS One 2014; 9(12): e115199.
Basit A, Basit KA, Fawward A, Shaheen F, Fatima N, Petropoulos N, et al. Vitamin D for the treatment of painful diabetic neu-ropathy. BMJ Open Diabetes Res Care 2016; 4(1): e000148.
Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111(13): 1666–71.
Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13(2): 101–7.
Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, et al. Contradictory effects of β1- and α1- aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI): CAVI independent of blood pressure. J Atheroscler Thromb 2011; 18(1): 49–55.
Suzuki J, Sakakibara R, Tomaru T, Tateno F, Kishi M, Ogawa E, Kurosu T, et al. Stroke and cardio-ankle vascular stiffness in-dex. J Stroke Cerebrovasc Dis 2013; 22(2): 171–5.
Miyoshi T, Doi M, Hirohata S, Sakane K, Kamikawa S, Kitawaki T, et al. Cardio-ankle vascular index is independently associat-ed with the severity of coronary atherosclerosis and left ven-tricular function in patients with ischemic heart disease. J Atheroscler Thromb 2010; 17(3): 249–58.
Kumagai T, Kasai T, Kato M, Naito R, Maeno K, Kasagi S, et al. Establishment of the cardio-ankle vascular index in patients with obstructive sleep apnea. Chest 2009; 136(3): 779–86.
Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of ar-terial stiffness: theory, evidence and perspectives. J Athero-scler Thromb 2011; 18(11): 924–38.
Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, et al. Inhibitory role of plasminogen activator inhibitor-1 in arte-rial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96(9): 3180–91.
Carmeliet P, Moons L, Stassen JM, De Mol M, Bouché A, van den Oord JJ, et al. Vascular wound healing and neointima for-mation induced by perivascular electric injury in mice. Am J Pathol 1997; 150(2): 761–76.
Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen R, Car-meliet P. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005; 3(5): 1018–25.
Gregory AD, Capoccia BJ, Woloszynek JR, Link DC. Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes. J Leukoc Biol 2010; 88(1): 123–31.
Jin DK, Shido K, Kopp H, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated deployment of SDF-1 induces revasculari-zation through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12(5): 557–67.
Oh CW, Hoover-Plow J, Plow EF. The role of plasminogen in an-giogenesis in vivo. J Thromb Haemost 2003; 1(8): 1683–734.
Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008; 15(3): 215–20.
Muhs BE, Plitas G, Delgado Y, Ianus I, Shaw JP, Adelman MA, et al. Temporal expression and activation of matrix metallo-proteinases-2, -9, and membrane type 1-matrix metallopro-teinase following acute hindlimb ischemia. J Surg Res 2003; 111(1): 8–15.
Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson-Welsh L. FGFR-1 regulates angiogenesis through cytokines in-terleukin-4 and pleiotrophin. Blood 2007; 110(13): 4214–22.